{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:46:05Z","timestamp":1794008765041,"version":"4.8.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Pathology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.carpath.2020.107243","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T21:52:28Z","timestamp":1589838748000},"page":"107243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-2543","authenticated-orcid":false,"given":"David","family":"Ben-Nun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8386-7029","authenticated-orcid":false,"given":"L. Maximilian","family":"Buja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Cv","key":"10.1016\/j.carpath.2020.107243_bib0001","article-title":"Targeting endothelial function to treat heart failure with preserved ejection fraction: the promise of exercise training","volume":"2017","author":"Gevaert","year":"2017","journal-title":"Oxid Med Cell Longev"},{"issue":"11","key":"10.1016\/j.carpath.2020.107243_bib0002","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/hrt.2005.074187","article-title":"Heart failure with a normal ejection fraction","volume":"93","author":"Sanderson","year":"2007","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.carpath.2020.107243_bib0004","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0005","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0006","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"issue":"20","key":"10.1016\/j.carpath.2020.107243_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 Inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.carpath.2020.107243_bib0008","doi-asserted-by":"crossref","DOI":"10.1007\/s11936-019-0709-4","article-title":"Treatment of heart failure with preserved ejection fraction (HFpEF): the phenotype-guided approach","volume":"21","author":"Silverman","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.carpath.2020.107243_bib0009","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.carpath.2008.02.004","article-title":"Cardiomyocyte death and renewal in the normal and diseased heart","volume":"17","author":"Maximilian Buja","year":"2008","journal-title":"Cardiovasc Pathol"},{"issue":"November 2018","key":"10.1016\/j.carpath.2020.107243_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yjmcc.2019.01.022","article-title":"Cardiac repair and the putative role of stem cells","volume":"128","author":"Buja","year":"2019","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"10.1016\/j.carpath.2020.107243_bib0012","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCULATIONAHA.117.029343","article-title":"Cardiomyocyte regeneration: a consensus statement","volume":"136","author":"Eschenhagen","year":"2017","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.carpath.2020.107243_bib0013","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/emmm.201100175","article-title":"Regeneration of the heart","volume":"3","author":"Steinhauser","year":"2011","journal-title":"EMBO Mol Med"},{"issue":"23","key":"10.1016\/j.carpath.2020.107243_bib0014","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200106073442303","article-title":"Evidence that human cardiac myocytes divide after myocardial infarction","volume":"344","author":"Beltrami","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0735-1097(99)00014-5","article-title":"50th anniversary historical article. Heart failure","volume":"33","author":"Francis","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2020.107243_bib0016","article-title":"Signaling pathways in cardiac myocyte apoptosis","author":"Xia","year":"2016","journal-title":"Biomed Res Int. 2016"},{"issue":"16","key":"10.1016\/j.carpath.2020.107243_bib0017","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJM199704173361603","article-title":"Apoptosis in the failing human heart","volume":"336","author":"Olivetti","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0018","first-page":"3","article-title":"Apoptosis, oncosis, and necrosis: an overview of cell death","volume":"146","author":"Majno","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.carpath.2020.107243_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(60)90084-9","article-title":"Heart failure from the point of view of quantitative anatomy*","author":"Linzbach","year":"1960","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.carpath.2020.107243_bib0020","first-page":"3\u201421","article-title":"Quantitative morphology and structural dynamics of the myocardium","volume":"5","author":"Hort","year":"1971","journal-title":"Methods Achiev Exp Pathol"},{"issue":"4","key":"10.1016\/j.carpath.2020.107243_bib0021","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0022","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.carpath.2020.107243_bib0023","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Hear Fail"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0024","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","article-title":"Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model","volume":"6","author":"Hamdani","year":"2013","journal-title":"Circ Hear Fail"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol Rev"},{"issue":"25","key":"10.1016\/j.carpath.2020.107243_bib0026","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.jacc.2019.10.036","article-title":"Transition of macrophages to fibroblast-like cells in healing myocardial infarction","volume":"74","author":"Haider","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2020.107243_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2019.10.031","article-title":"The Myocardium: more than myocytes","author":"Libby","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.carpath.2020.107243_bib0028","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1083\/jcb.201208082","article-title":"Discovering the first microrna-targeted drug","volume":"199","author":"Lindow","year":"2012","journal-title":"J Cell Biol"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0029","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/cvr\/cvy049","article-title":"Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle","volume":"114","author":"Rech","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"5543","key":"10.1016\/j.carpath.2020.107243_bib0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.1064921","article-title":"Identification of novel genes coding for small expressed RNAs","volume":"294","author":"Lagos-Quintana","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.carpath.2020.107243_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0056280","article-title":"miR-21 Promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving programmed cell death 4 and sprouty-1","volume":"8","author":"Br\u00f8nnum","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0033","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2353\/ajpath.2007.061170","article-title":"MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a pole in cardiac hypertrophy?","volume":"170","author":"Cheng","year":"2007","journal-title":"Am J Pathol"},{"issue":"48","key":"10.1016\/j.carpath.2020.107243_bib0034","doi-asserted-by":"crossref","first-page":"18255","DOI":"10.1073\/pnas.0608791103","article-title":"A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure","volume":"103","author":"Van Rooij","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.carpath.2020.107243_bib0035","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrd3864","article-title":"MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles","volume":"11","author":"Van Rooij","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0036","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ejhf.1119","article-title":"Transcoronary concentration gradients of circulating microRNAs in heart failure","volume":"20","author":"De Rosa","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"10.1016\/j.carpath.2020.107243_bib0037","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.jacc.2016.09.945","article-title":"MicroRNAs in cardiovascular disease","volume":"68","author":"Barwari","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.carpath.2020.107243_bib0038","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/138945010791591403","article-title":"MicroRNA-21: from cancer to cardiovascular disease","volume":"11","author":"Jazbutyte","year":"2010","journal-title":"Curr Drug Targets"},{"issue":"3","key":"10.1016\/j.carpath.2020.107243_bib0039","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12265-010-9169-7","article-title":"MicroRNA-21 in cardiovascular disease","volume":"3","author":"Cheng","year":"2010","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.carpath.2020.107243_bib0040","first-page":"1","article-title":"Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease","volume":"1934","author":"Kaur","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.carpath.2020.107243_bib0041","doi-asserted-by":"crossref","unstructured":"Huang Z., Chen X., Qian C., Dong Q. Signal Transducer and Activator of Transcription 3\/ MicroRNA-21 Feedback Loop Contributes to Atrial Fibrillation by Promoting Atrial Fibrosis in a Rat Sterile Pericarditis Model. 2016;1\u201313.","DOI":"10.1161\/CIRCEP.115.003396"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0042","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/ddr.21257","article-title":"The role of MIR-21 in cancer","volume":"76","author":"Pfeffer","year":"2015","journal-title":"Drug Dev Res"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0043","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/jcb.26300","article-title":"MiR-21: a key player in glioblastoma pathogenesis","volume":"119","author":"Masoudi","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.carpath.2020.107243_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoto.2019.2427","article-title":"Prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma","author":"Spector","year":"2019","journal-title":"JAMA Otolaryngol - Head Neck Surg"},{"issue":"10","key":"10.1016\/j.carpath.2020.107243_bib0045","first-page":"4149","article-title":"MiR-21 regulates the proliferation and apoptosis of ovarian cancer cells through PTEN\/PI3K\/AKT","volume":"23","author":"Liu","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"10.1016\/j.carpath.2020.107243_bib0046","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s13238-013-3085-y","article-title":"MicroRNA-21 in the pathogenesis of acute kidney injury","volume":"4","author":"Li","year":"2013","journal-title":"Protein Cell"},{"issue":"19","key":"10.1016\/j.carpath.2020.107243_bib0047","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s00018-018-2877-x","article-title":"Overview upon miR-21 in lung cancer: focus on NSCLC","volume":"75","author":"Bica-Pop","year":"2018","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0048","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti\u2013microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.carpath.2020.107243_bib0049","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20100035","article-title":"miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis","volume":"207","author":"Liu","year":"2010","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.carpath.2020.107243_bib0050","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI70577","article-title":"Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy","volume":"124","author":"Bang","year":"2014","journal-title":"J Clin Invest"},{"issue":"7224","key":"10.1016\/j.carpath.2020.107243_bib0051","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.carpath.2020.107243_bib0052","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","article-title":"Myocardial interstitial fibrosis in heart failure: biological and translational perspectives","volume":"71","author":"Gonz\u00e1lez","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.carpath.2020.107243_bib0053","first-page":"1","article-title":"Circulating biomarkers of cardiac fibrosis: do we have any and what use are they?","volume":"10","author":"Richards","year":"2017","journal-title":"Circ Hear Fail"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0054","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10741-012-9365-4","article-title":"Fibrosis and heart failure","volume":"19","author":"Segura","year":"2014","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCRESAHA.115.302929","article-title":"Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium","volume":"115","author":"Loffredo","year":"2014","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.carpath.2020.107243_bib0056","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.3892\/etm.2017.4246","article-title":"Transforming growth factor \u03b2 and its role in heart disease","volume":"13","author":"Liu","year":"2017","journal-title":"Exp Ther Med"},{"issue":"12","key":"10.1016\/j.carpath.2020.107243_bib0057","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.biocel.2012.08.019","article-title":"A novel reciprocal loop between microRNA-21 and TGF\u03b2RIII is involved in cardiac fibrosis","volume":"44","author":"Liang","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0058","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/cvr\/cvp015","article-title":"MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue","volume":"82","author":"Roy","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.carpath.2020.107243_bib0059","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1073\/pnas.83.12.4167","article-title":"Transforming growth factor type \u03b2: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro","volume":"83","author":"Roberts","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0060","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1159\/000479995","article-title":"Mir-21 promotes cardiac fibrosis after myocardial infarction via targeting Smad7","volume":"42","author":"Yuan","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"10.1016\/j.carpath.2020.107243_bib0061","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1159\/000445554","article-title":"Celastrol-induced suppression of the MiR- 21\/ERK signalling pathway attenuates cardiac fibrosis and dysfunction","volume":"38","author":"Cheng","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0062","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/ATVBAHA.111.234286","article-title":"Transforming growth factor-\u03b2-induced endothelial-to-mesenchymal transition is partly mediated by MicroRNA-21","volume":"32","author":"Kumarswamy","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0063","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.yjmcc.2009.01.008","article-title":"MicroRNA-21 protects against the H2O2-induced injury on cardiac myocytes via its target gene PDCD4","volume":"47","author":"Cheng","year":"2009","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0064","first-page":"565","article-title":"microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2","volume":"7","author":"Dong","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"32","key":"10.1016\/j.carpath.2020.107243_bib0065","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/eurheartj\/ehv109","article-title":"Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis","volume":"36","author":"Lorenzen","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0066","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1210\/en.2016-1707","article-title":"Role and regulation of microRNAs in aldosterone-mediated cardiac injury and dysfunction in male rats","volume":"158","author":"Ball","year":"2017","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0067","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.kint.2017.05.014","article-title":"MicroRNA-21 regulates peroxisome proliferator\u2013activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4","volume":"93","author":"Chuppa","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0068","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1152\/ajpheart.00037.2007","article-title":"Role of oxidative stress in cardiac dysfunction of PPAR\u03b1 -\/- mice","volume":"293","author":"Guellich","year":"2007","journal-title":"Am J Physiol - Hear Circ Physiol"},{"issue":"3","key":"10.1016\/j.carpath.2020.107243_bib0069","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/cvr\/cvv026","article-title":"MiR-21: a star player in cardiac hypertrophy","volume":"105","author":"Duygu","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"11","key":"10.1016\/j.carpath.2020.107243_bib0070","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1172\/JCI43604","article-title":"Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice","volume":"120","author":"Patrick","year":"2010","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.carpath.2020.107243_bib0071","doi-asserted-by":"crossref","first-page":"E1154","DOI":"10.1152\/ajpendo.00155.2018","article-title":"Microrna-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction","volume":"315","author":"Syed","year":"2018","journal-title":"Am J Physiol - Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.carpath.2020.107243_bib0072","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cvr\/cvu254","article-title":"MiR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8","volume":"105","author":"Yan","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"30","key":"10.1016\/j.carpath.2020.107243_bib0073","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1016\/j.febslet.2008.11.014","article-title":"Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia-reperfusion in mice","volume":"582","author":"Yin","year":"2008","journal-title":"FEBS Lett"},{"issue":"43","key":"10.1016\/j.carpath.2020.107243_bib0074","doi-asserted-by":"crossref","first-page":"29514","DOI":"10.1074\/jbc.M109.027896","article-title":"MicroRNA expression signature and the role of MicroRNA-21 in the early phase of acute myocardial infarction","volume":"284","author":"Dong","year":"2009","journal-title":"J Biol Chem"},{"issue":"26","key":"10.1016\/j.carpath.2020.107243_bib0075","doi-asserted-by":"crossref","first-page":"20281","DOI":"10.1074\/jbc.M110.109207","article-title":"MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of fas ligand","volume":"285","author":"Sayed","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0076","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1172\/JCI46108","article-title":"Response to Thum et\u00a0al","volume":"121","author":"Patrick","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0077","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1172\/JCI45938","article-title":"Comparison of different miR-21 inhibitor chemistries in a cardiac disease model","volume":"121","author":"Thum","year":"2011","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.carpath.2020.107243_bib0078","first-page":"613","article-title":"FDA approves landmark RNAi drug","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"10.1016\/j.carpath.2020.107243_bib0079","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.carpath.2020.107243_bib0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0081","first-page":"114","article-title":"How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market","volume":"30","author":"Bonneau","year":"2019","journal-title":"Electron J Int Fed Clin Chem Lab Med"},{"issue":"7","key":"10.1016\/j.carpath.2020.107243_bib0082","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s11095-017-2134-2","article-title":"The race of 10 synthetic RNAi-based drugs to the pharmaceutical market","volume":"34","author":"Titze-de-Almeida","year":"2017","journal-title":"Pharm Res"},{"issue":"18","key":"10.1016\/j.carpath.2020.107243_bib0083","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0084","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ymthe.2016.08.001","article-title":"Therapeutic miR-21 silencing ameliorates diabetic kidney disease in mice","volume":"25","author":"K\u00f6lling","year":"2017","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.carpath.2020.107243_bib0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/hum.2018.205","article-title":"Dysregulated expression of microRNA-21 and disease-related genes in human patients and in a mouse model of alport syndrome","volume":"30","author":"Guo","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.carpath.2020.107243_bib0086","unstructured":"A Study of RG-012 in Subjects With Alport Syndrome [Internet]. [cited 2020 Jan 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03373786 Accessed: Dec 19, 2019."},{"key":"10.1016\/j.carpath.2020.107243_bib0087","unstructured":"Study of SAR339375 in Patients With Alport Syndrome [Internet]. [cited 2020 Jan 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02855268 Accessed: Dec 19, 2019."},{"issue":"7774","key":"10.1016\/j.carpath.2020.107243_bib0088","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.carpath.2020.107243_bib0089","unstructured":"Phimister E.G., Hill J.A.When the CAR Targets Scar. 2019;"},{"issue":"23","key":"10.1016\/j.carpath.2020.107243_bib0090","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.0000038705.69871.D9","article-title":"Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction","volume":"106","author":"Weinberg","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0091","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0092","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14017431.2019.1583363","article-title":"ST2 in heart failure with preserved and reduced ejection fraction","volume":"53","author":"Najjar","year":"2019","journal-title":"Scand Cardiovasc J"},{"issue":"2","key":"10.1016\/j.carpath.2020.107243_bib0093","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004382","article-title":"Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.carpath.2020.107243_bib0094","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/JAHA.117.007885","article-title":"Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"7","author":"Duprez","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carpath.2020.107243_bib0095","doi-asserted-by":"crossref","unstructured":"Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. 35888. Nature. 1998;391(February):806\u201311.","DOI":"10.1038\/35888"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0096","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ejhf.1044","article-title":"microRNA-132: a new biomarker of heart failure at last?","volume":"20","author":"Panico","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.carpath.2020.107243_bib0097","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ncomms2090","article-title":"The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy","volume":"3","author":"Ucar","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.carpath.2020.107243_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2017.03.003","article-title":"Inhibition of miRNA-212\/132 improves the reprogramming of fibroblasts into induced pluripotent stem cells by de-repressing important epigenetic remodelling factors","author":"Pfaff","year":"2017","journal-title":"Stem Cell Res"},{"issue":"1","key":"10.1016\/j.carpath.2020.107243_bib0099","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-pharmtox-011613-135957","article-title":"microRNA therapeutics in cardiovascular disease models","volume":"54","author":"Dangwal","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.carpath.2020.107243_bib0100","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nm1582","article-title":"MicroRNA-133 controls cardiac hypertrophy","volume":"13","author":"Car\u00e8","year":"2007","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.carpath.2020.107243_bib0101","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrcardio.2014.125","article-title":"Noncoding RNAs and myocardial fibrosis","volume":"11","author":"Thum","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"13","key":"10.1016\/j.carpath.2020.107243_bib0102","article-title":"Antifibrotic therapies to control cardiac fibrosis","volume":"20","author":"Fan","year":"2016","journal-title":"Biomater Res"}],"container-title":["Cardiovascular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054880720300478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054880720300478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:45:47Z","timestamp":1760960747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054880720300478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":102,"alternative-id":["S1054880720300478"],"URL":"https:\/\/doi.org\/10.1016\/j.carpath.2020.107243","relation":{},"ISSN":["1054-8807"],"issn-type":[{"value":"1054-8807","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carpath.2020.107243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107243"}}